Overview

Properties

Applications

Our Abpromise guarantee covers the use of ab33917 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500. Detects a band of approximately 70 kDa (predicted molecular weight: 62 kDa).
IHC-P 1/100 - 1/250.
IP 1/50.
ICC/IF 1/250 - 1/500.
  • Application notesIs unsuitable for Flow Cyt.
  • Target

    • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.
    • Sequence similaritiesContains 1 RHD (Rel-like) domain.
    • DomainBoth N- and C-terminal domains are required for transcriptional activation.
    • Post-translational
      modifications
      Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.
    • Cellular localizationNucleus. Cytoplasm > cytoskeleton > centrosome. Co-localizes with NEK6 in the centrosome.
    • Information by UniProt
    • Database links
    • Alternative names
      • I REL antibody
      • I-Rel antibody
      • IREL antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody
      • relB antibody
      • RELB_HUMAN antibody
      • Reticuloendotheliosis viral oncogene homolog B antibody
      • Transcription factor Rel B antibody
      • Transcription factor RelB antibody
      • v rel avian reticuloendotheliosis viral oncogene homolog B antibody
      • v rel reticuloendotheliosis viral oncogene homolog B antibody
      see all

    Anti-Rel B antibody [EP613Y] images

    • Immunohistochemical analysis of paraffin-embedded human lymphoma using ab33917
    • All lanes : Anti-Rel B antibody [EP613Y] (ab33917) at 1/500 dilution

      Lane 1 : 10ug Raji cell lysate
      Lane 2 : 10ug Daudi cell lysate

      Secondary
      Goat anti-rabbit HRP labeled.

      Predicted band size : 62 kDa

    References for Anti-Rel B antibody [EP613Y] (ab33917)

    This product has been referenced in:
    • Siak JJ  et al. The nuclear-factor kappaB pathway is activated in pterygium. Invest Ophthalmol Vis Sci 52:230-6 (2011). Read more (PubMed: 20811049) »
    • Huang Y  et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115:1226-37 (2010). Read more (PubMed: 19965620) »

    See all 2 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab33917.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"